CME/CE

Host: Christopher J. Richards, MD Host: Ashley Losier, MD Bronchiectasis is complex, often underdiagnosed, and frequently misunderstood. Explore key contributors to disease progression, including the role of neutrophilic inflammation and neutrophilic serine proteases, and learn to distinguish bronchiectasis from other respiratory conditions and assess patient risk factors that impact outcomes. Thi...

Faculty: Kenneth Lieberman, MD Faculty: Vladimir Tesar Managing patients with focal segmental glomerulosclerosis, or FSGS, can present certain challenges. FSGS is a serious, progressive condition that has no current FDA-approved treatment and standard of care therapy may not meet treatment goals for many patients. But the current use of patient-reported outcomes (PROs), as well as emerging treatme...

Faculty: Meghan Sise, MD Managing patients with focal segmental glomerulosclerosis, or FSGS, can present certain challenges. FSGS is a serious, progressive condition that has no current FDA-approved treatment and standard of care therapy may not meet treatment goals for many patients. But the current use of patient-reported outcomes (PROs), as well as emerging treatments on the horizon, may prove...

Faculty: Kenneth Lieberman, MD Managing patients with focal segmental glomerulosclerosis, or FSGS, can present certain challenges. FSGS is a serious, progressive condition that has no current FDA-approved treatment and standard of care therapy may not meet treatment goals for many patients. But the current use of patient-reported outcomes (PROs), as well as emerging treatments on the horizon, may...

Faculty: Vladimir Tesar Faculty: Meghan Sise, MD Managing patients with focal segmental glomerulosclerosis, or FSGS, can present certain challenges. FSGS is a serious, progressive condition that has no current FDA-approved treatment and standard of care therapy may not meet treatment goals for many patients. But the current use of patient-reported outcomes (PROs), as well as emerging treatments on...

Faculty: Meghan Sise, MD Faculty: Vladimir Tesar Managing patients with focal segmental glomerulosclerosis, or FSGS, can present certain challenges. FSGS is a serious, progressive condition that has no current FDA-approved treatment and standard of care therapy may not meet treatment goals for many patients. But the current use of patient-reported outcomes (PROs), as well as emerging treatments on...

Faculty: Vladimir Tesar Faculty: Meghan Sise, MD Managing patients with focal segmental glomerulosclerosis, or FSGS, can present certain challenges. FSGS is a serious, progressive condition that has no current FDA-approved treatment and standard of care therapy may not meet treatment goals for many patients. But the current use of patient-reported outcomes (PROs), as well as emerging treatments on...

Faculty: Vladimir Tesar Faculty: Meghan Sise, MD Managing patients with focal segmental glomerulosclerosis, or FSGS, can present certain challenges. FSGS is a serious, progressive condition that has no current FDA-approved treatment and standard of care therapy may not meet treatment goals for many patients. But the current use of patient-reported outcomes (PROs), as well as emerging treatments on...

Faculty: Vladimir Tesar Faculty: Meghan Sise, MD Managing patients with focal segmental glomerulosclerosis, or FSGS, can present certain challenges. FSGS is a serious, progressive condition that has no current FDA-approved treatment and standard of care therapy may not meet treatment goals for many patients. But the current use of patient-reported outcomes (PROs), as well as emerging treatments on...

Faculty: Meghan Sise, MD Managing patients with focal segmental glomerulosclerosis, or FSGS, can present certain challenges. FSGS is a serious, progressive condition that has no current FDA-approved treatment and standard of care therapy may not meet treatment goals for many patients. But the current use of patient-reported outcomes (PROs), as well as emerging treatments on the horizon, may prove...

Faculty: Marion Munk, MD, Ph. D Faculty: David Boyer, MD This CME activity focuses on multiwavelength photobiomodulation (PBM), an emerging therapy indicated for the treatment of dry age-related macular degeneration (AMD). Hear from leading researchers and retina specialists about the mechanism of action, how it is administered, its efficacy and safety profile, therapeutic durability, which patien...

Faculty: David Boyer, MD Faculty: Marion Munk, MD, Ph. D This CME activity focuses on multiwavelength photobiomodulation (PBM), an emerging therapy indicated for the treatment of dry age-related macular degeneration (AMD). Hear from leading researchers and retina specialists about the mechanism of action, how it is administered, its efficacy and safety profile, therapeutic durability, which patien...

Faculty: Diana V. Do, MD Faculty: Marion Munk, MD, Ph. D This CME activity focuses on multiwavelength photobiomodulation (PBM), an emerging therapy indicated for the treatment of dry age-related macular degeneration (AMD). Hear from leading researchers and retina specialists about the mechanism of action, how it is administered, its efficacy and safety profile, therapeutic durability, which patien...

Faculty: Marion Munk, MD, Ph. D Faculty: Diana V. Do, MD This CME activity focuses on multiwavelength photobiomodulation (PBM), an emerging therapy indicated for the treatment of dry age-related macular degeneration (AMD). Hear from leading researchers and retina specialists about the mechanism of action, how it is administered, its efficacy and safety profile, therapeutic durability, which patien...

Faculty: Marion Munk, MD, Ph. D Faculty: David Boyer, MD This CME activity focuses on multiwavelength photobiomodulation (PBM), an emerging therapy indicated for the treatment of dry age-related macular degeneration (AMD). Hear from leading researchers and retina specialists about the mechanism of action, how it is administered, its efficacy and safety profile, therapeutic durability, which patien...

Faculty: Diana V. Do, MD Faculty: David Boyer, MD This CME activity focuses on multiwavelength photobiomodulation (PBM), an emerging therapy indicated for the treatment of dry age-related macular degeneration (AMD). Hear from leading researchers and retina specialists about the mechanism of action, how it is administered, its efficacy and safety profile, therapeutic durability, which patients may...

Faculty: David Boyer, MD Faculty: Diana V. Do, MD This CME activity focuses on multiwavelength photobiomodulation (PBM), an emerging therapy indicated for the treatment of dry age-related macular degeneration (AMD). Hear from leading researchers and retina specialists about the mechanism of action, how it is administered, its efficacy and safety profile, therapeutic durability, which patients may...

Guest: Janis T. Eells, Ph. D. This CME activity focuses on multiwavelength photobiomodulation (PBM), an emerging therapy indicated for the treatment of dry age-related macular degeneration (AMD). Hear from leading researchers and retina specialists about the mechanism of action, how it is administered, its efficacy and safety profile, therapeutic durability, which patients may benefit the most, an...

Host: Jaime Almandoz, MD, MBA, MRCPI, FTOS, DABOM Guest: Daniel C. Butler, MD Guest: Benjamin Ungar, MD On-demand webcast of expert faculty presentation on the key connection between psoriasis and obesity, including comprehensive treatment strategies that consider outcomes improvement for both diseases.

Host: Stella Lee, MD Guest: Katie Buchheit, MD Guest: Michael E. Wechsler, MD, MMSc Chronic rhinosinusitis with nasal polyps (CRSwNP) presents a large burden on more than 3 million patients with the conditions — especially when intertwined with asthma and allergy. Join our discussion between patients with CRSwNP and leading experts in ENT, allergy, and pulmonary medicine as they: Breakdown how to...

Faculty: Durga Borkar, MD, MMCi Faculty: Veeral Sheth, MD, MBA, FASRS, FACS Wondering how your practice’s use of next-generation retinal agents compares to the experts? Join Dr. Durga Borkar and Dr. Veeral Sheth as they discuss how they are using next-generation agents to free their patients from frequent office visits.

Faculty: Durga Borkar, MD, MMCi Faculty: Veeral Sheth, MD, MBA, FASRS, FACS Need to catch up on the latest data surrounding next-generation retinal treatments? Drs. Veeral Sheth and Durga Borkar walk through the most recent efficacy and safety data around faricimab, aflibercept 8 mg, and the PDS with ranibizumab. They also review the latest insights on the use of these treatments in real-world pra...

In this episode of KDIGO Conversations in Nephrology, Dr. Carla Nester is joined by Marianne Silkjaer Nielsen. Not only is Ms. Nielsen the mother of a girl who lives with immune complex-MPGN, but she’s also the founder of CompCure, a not-for-profit association that is dedicated to improving outcomes in patients with C3G and immune complex-MPGN . Together, their conversation will cover: The Diagnos...

In this episode of KDIGO Conversations in Nephrology, Dr. Carla Nester is joined by Dr. Nicole van de Kar, Professor of Pediatrics at Radboud University Medical Center in the Netherlands, to discuss the role of complement in C3 glomerulopathy (C3G). They begin by defining C3G and exploring its pathophysiology, specifically focusing on the overactivation of the alternative pathway of the complement...

In this episode of KDIGO Conversations in Nephrology, Dr. Carla Nester is joined by Dr. David Kavanagh, Professor of Complement Therapeutics at the National Renal Complement Therapeutic Centre in Newcastle, England, to discuss the diagnosis and management of C3 glomerulopathy (C3G). They cover how patients present and the diagnostic workup required to confirm the diagnosis and rule out other disea...